ChiCTR2500108080 版本V1.0 版本创建时间2025/08/25 10:15:15 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500108080 

最近更新日期:

Date of Last Refreshed on:

2025-08-25 10:15:07 

注册时间:

Date of Registration:

2025-08-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

离焦框架眼镜联合0.01%阿托品滴眼液对屈光参差性近视儿童的近视控制效果分析

Public title:

A Comparison of myopia control efficacy in Chinese children with myopia control spectacles (MCS) and combined MCS and atropine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

离焦框架眼镜联合0.01%阿托品滴眼液对屈光参差性近视儿童的近视控制效果分析

Scientific title:

A Comparison of myopia control efficacy in Chinese children with myopia control spectacles (MCS) and combined MCS and atropine

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨必 

研究负责人:

杨必 

Applicant:

Yang Bi 

Study leader:

Yang Bi 

申请注册联系人电话:

Applicant telephone:

+86 136 8840 4467

研究负责人电话:

Study leader's telephone:

+86 136 8840 4467

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

53587134@qq.com

研究负责人电子邮件:

Study leader's E-mail:

53587134@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

No. 37, Guoxue valley, Wuhou district, Chengdu city, Sichuan province

Study leader's address:

No. 37, Guoxue valley, Wuhou district, Chengdu city, Sichuan province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

West hospital, Sichuan univerisity

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West hospital, Sichuan univerisity

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年审(2177)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华医院生物医学伦理审查委员会

Name of the ethic committee:

Biomedical Ethics Review Committee of West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-19 00:00:00

伦理委员会联系人:

邓绍林

Contact Name of the ethic committee:

Deng Shaolin

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

No. 37, Guoxue valley, Wuhou district, Chengdu city, Sichuan province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8542 2654

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West hospital, Sichuan univerisity

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

No. 37, Guoxue valley, Wuhou district, Chengdu city, Sichuan province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China hospital, Sichuan univerisity

Address:

No. 37, Guoxue valley, Wuhou district, Chengdu city, Sichuan province

经费或物资来源:

四川省科技厅重点研发计划(重大科技专项)项目

Source(s) of funding:

Sichuan Provincial Department of Science and Technology

Target disease:

myopia

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.比较联合疗法与单一光学手段对屈光参差性近视儿童的近视控制有效性是否存在差异; 2.比较屈光参差性近视儿童使用联合疗法或单一光学手段时,双眼间的近视控制有效性是否存在差异。  

Objectives of Study:

1. To compare whether there is a difference in the effectiveness of combination therapy and single optical means in myopia control in children with anisometropic myopia; 2. To compare whether there is a difference in the effectiveness of myopia control between the two eyes when children with anisometric myopia use combination therapy or a single optical method.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄:6~12岁; 2.双眼近视:-5.75 D ~ -0.50 D (等效球镜度 >= -5.75); 3.双眼散光屈光度<=1.50D; 4.屈光参差:1.00 D ~ 3.00 D; 5.双眼最佳矫正视力>= 20/25; 6.眼部健康情况良好; 7.双眼视功能正常。

Inclusion criteria

1. Age: 6~12 years old; 2. Myopia in both eyes: -5.75 D ~ -0.50 D (equivalent spherical magnology >= -5.75); 3. Astigmatism diopter in both eyes<=1.50D; 4. Diactive variance: 1.00 D ~ 3.00 D; 5. Best corrected visual acuity in both eyes> = 20/25; 6. Good eye health; 7. Normal binocular visual function.

排除标准:

1.罹患眼病如角结膜炎、青光眼、斜视等; 2.已使用过其他近视控制方法,如OK镜、阿托品、离焦框架眼镜; 3.依从性差,不能按时随访; 4.拒绝随机分组.

Exclusion criteria:

1. Suffering from eye diseases such as keratoconjunctivitis, glaucoma, strabismus, etc.; 2. Other myopia control methods have been used, such as OK lenses, atropine, and defocus glasses; 3. Poor compliance and inability to follow up on time; 4. Refuse randomization.

研究实施时间:

Study execute time:

From 2025-09-01 00:00:00 To 2026-10-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-09-30 00:00:00 To 2026-09-30 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

45

Group:

Experimental group

Sample size:

干预措施:

离焦框架眼镜联合0.01%阿托品滴眼液

干预措施代码:

Intervention:

MCS combined with 0.01%atropine

Intervention code:

组别:

对照组

样本量:

45

Group:

Control group

Sample size:

干预措施:

离焦框架眼镜

干预措施代码:

Intervention:

MCS

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan  

City:

Chengdu  

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China hospital, Sichuan university

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

眼轴

指标类型:

主要指标

Outcome:

Axial length

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

等效球镜度

指标类型:

主要指标

Outcome:

Spherical equivalent refraction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

最佳矫正视力

指标类型:

次要指标

Outcome:

Best corrected visual acuity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

对比敏感度

指标类型:

次要指标

Outcome:

Contrast sensitivity test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

使用excel生成随机数

Randomization Procedure (please state who generates the random number sequence and by what method):

randomization with an excel spreadsheet

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对主要指标测量者设盲

Blinding:

The measurement of the main indicators is blinded

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-08-25 10:15:07